Lotte Biologics' U.S. CDMO Contract and Songdo Campus Momentum: Analysis Report

Market situation summary and analysis 

Lotte Biologics has signed a CDMO contract with a U.S. oncology-focused biotech company for the production and process development of antibody drug substance (DS). 

 

Under this contract, Lotte Biologics will be responsible for producing key clinical materials needed for the partner's global late-stage clinical trials, 

and the work will be carried out using the infrastructure of its Syracuse Bio Campus in New York, U.S.

 

The key strategic significance of the contract 

This contract is a strategic move toward the successful operation of Plant 1 at the Songdo Bio Campus, which is due to be completed in the second half of this year. 

 

For the Songdo campus, which will have a massive production capacity of 120,000 liters for antibody drugs, securing global customers before operations begin was the top priority. 

 

This contract with a U.S. company will serve as a strong 'reference' proving its technology and reliability, acting as the seed that draws in major follow-on contracts in the future.

 

Implications from an investor's perspective 

Given the nature of the bio CDMO business, early-stage process development and clinical material production partnerships have a lock-in effect that leads directly to large-scale commercial manufacturing (CMO) orders once a new drug is approved. 

 

Although the specific size of this contract has not been disclosed, since it is a late-stage clinical project, enormous added value is expected if it succeeds. 

 

Investors should watch for the possibility of additional order momentum from global big pharma coinciding with the completion of Songdo Plant 1, now about 4 months away, and keep an eye on shifts in investor sentiment across the bio value chain.